282 related articles for article (PubMed ID: 24294176)
1. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies.
Schmitt M; Magdolen V; Yang F; Kiechle M; Bayani J; Yousef GM; Scorilas A; Diamandis EP; Dorn J
Radiol Oncol; 2013; 47(4):319-29. PubMed ID: 24294176
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies.
Dorn J; Bayani J; Yousef GM; Yang F; Magdolen V; Kiechle M; Diamandis EP; Schmitt M
Thromb Haemost; 2013 Sep; 110(3):408-22. PubMed ID: 23765253
[TBL] [Abstract][Full Text] [Related]
3. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
Avgeris M; Scorilas A
Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
[TBL] [Abstract][Full Text] [Related]
4. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers.
Emami N; Diamandis EP
Clin Chem; 2008 Oct; 54(10):1600-7. PubMed ID: 18687738
[TBL] [Abstract][Full Text] [Related]
5. Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines.
Shaw JL; Diamandis EP
Biol Chem; 2008 Nov; 389(11):1409-19. PubMed ID: 19031603
[TBL] [Abstract][Full Text] [Related]
6. Kallikrein-related peptidases and associated microRNAs as promising prognostic biomarkers in gastrointestinal malignancies.
Adamopoulos PG; Tsiakanikas P; Scorilas A
Biol Chem; 2018 Jul; 399(8):821-836. PubMed ID: 29883317
[TBL] [Abstract][Full Text] [Related]
7. Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.
Filippou PS; Karagiannis GS; Musrap N; Diamandis EP
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):277-91. PubMed ID: 26886390
[TBL] [Abstract][Full Text] [Related]
8. The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer.
Riedel M; Bronger H; Magdolen V; Dreyer T
Expert Rev Mol Diagn; 2021 Jun; 21(6):535-545. PubMed ID: 33947310
[No Abstract] [Full Text] [Related]
9. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).
Goettig P; Magdolen V; Brandstetter H
Biochimie; 2010 Nov; 92(11):1546-67. PubMed ID: 20615447
[TBL] [Abstract][Full Text] [Related]
10. Activation profiles and regulatory cascades of the human kallikrein-related peptidases.
Yoon H; Laxmikanthan G; Lee J; Blaber SI; Rodriguez A; Kogot JM; Scarisbrick IA; Blaber M
J Biol Chem; 2007 Nov; 282(44):31852-64. PubMed ID: 17823117
[TBL] [Abstract][Full Text] [Related]
11. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
Figueroa CD; Molina L; Bhoola KD; Ehrenfeld P
Biol Chem; 2018 Sep; 399(9):937-957. PubMed ID: 29885274
[TBL] [Abstract][Full Text] [Related]
12. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
Pampalakis G; Sotiropoulou G
Biochim Biophys Acta; 2007 Sep; 1776(1):22-31. PubMed ID: 17629406
[TBL] [Abstract][Full Text] [Related]
13. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract][Full Text] [Related]
14. Targeting kallikrein-related peptidases in prostate cancer.
Mavridis K; Avgeris M; Scorilas A
Expert Opin Ther Targets; 2014 Apr; 18(4):365-83. PubMed ID: 24571737
[TBL] [Abstract][Full Text] [Related]
15. Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.
Yoon H; Blaber SI; Evans DM; Trim J; Juliano MA; Scarisbrick IA; Blaber M
Protein Sci; 2008 Nov; 17(11):1998-2007. PubMed ID: 18697857
[TBL] [Abstract][Full Text] [Related]
16. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers.
Kontos CK; Scorilas A
Clin Chem Lab Med; 2012 Nov; 50(11):1877-91. PubMed ID: 23093268
[TBL] [Abstract][Full Text] [Related]
17. Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application.
Fuhrman-Luck RA; Loessner D; Clements JA
EJIFCC; 2014 Oct; 25(3):269-81. PubMed ID: 27683474
[TBL] [Abstract][Full Text] [Related]
18. KLK-targeted Therapies for Prostate Cancer.
Hannu K; Johanna M; Ulf-Håkan S
EJIFCC; 2014 Sep; 25(2):207-18. PubMed ID: 27683469
[TBL] [Abstract][Full Text] [Related]
19. Evolutionary history of tissue kallikreins.
Pavlopoulou A; Pampalakis G; Michalopoulos I; Sotiropoulou G
PLoS One; 2010 Nov; 5(11):e13781. PubMed ID: 21072173
[TBL] [Abstract][Full Text] [Related]
20. Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer.
Loessner D; Goettig P; Preis S; Felber J; Bronger H; Clements JA; Dorn J; Magdolen V
Expert Opin Ther Targets; 2018 Sep; 22(9):745-763. PubMed ID: 30114962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
